SELLAS Life Sciences Group Inc

NASDAQ:SLS   3:55:46 PM EDT
8.80
+0.65 (+7.98%)
Products, Strategic Combinations

Sellas, 3D Medicines Announce Deal For Development, Commercialization Of Galinpepimut-S & GPS+ In Greater China

Published: 12/07/2020 13:50 GMT
SELLAS Life Sciences Group Inc (SLS) - Sellas Life Sciences and 3d Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-s (gps) and Gps+ in Greater China.
Sellas Life Sciences - to Potentially Get Up to $202 Million, Inclusive of $7.5 Million Upfront License Fee, $8 Million Near-term Milestones, Plus Tiered Royalties.
Sellas Life Sciences Group Inc - 3d Medicines to Lead Clinical Development and Commercialization of Gps and Gps+ in Greater China.
Sellas Life Sciences Group - Retains Sole Rights to Gps and Gps+ Outside of Greater China Area.